Fig 2: Integrative proteomic and transcriptomic surfaceome profiling of osteosarcoma. A, The workflow of the integrative proteomic and transcriptomic approach used to identify immunotherapeutic targets in osteosarcomas. B, Expression profile of the cell-surface proteins identified by mass spectrometry in osteosarcoma cell lines and PDX models. C, Expression profile of the 209 overexpressed surface protein-encoding genes in 98 patients with osteosarcoma from the TARGET database (TARGET OS) and 17 osteosarcoma cell lines that we analyzed (OSC). The 11 candidate surface proteins and the 4 candidates that overlapped with existing drug targets are marked. The 4-candidate targets (MT1-MMP, MRC2, CD276, and LRRC15) were highly expressed in most of the patient samples and cell lines.

Fig 3: Effects of pre-incubation of fibrocytes with a specific antibody against integrin β1 or the irrelevant isotype-matched control, and with ligands of the scavenger receptors (poly[I]) and Endo180 (uPA) on cell adhesion to human plasma fibronectin, human collagen I, human collagen IV, human collagen V or human collagen VI. Values are means ± S.D. from five independent experiments. The asterisk indicates statistically significant differences (P < 0.05) versus medium alone.

Fig 4: IHC staining showed high membranous positivity of MT1-MMP, MRC2, and CD276 in most osteosarcoma patient samples and PDXs. A–C, Representative membrane-staining examples of MT1-MMP in a patient sample (A), PDX (B), and testes (negative control; C). D–F, Representative membrane-staining examples of MRC2 in a patient sample (D), PDX (E), and placenta (negative control; F). G–I, Representative membrane-staining examples of CD276 in a patient sample (G), PDX (H), and placenta (mild positive; I). J and K, Summary of IHC staining H-score of MT1-MMP, MRC2, and CD276 in the tissue microarray for 37 patients with osteosarcoma (J) and 19 PDX models (K). Boxes indicate SD, and error bars represent data range.

Fig 5: (a) (I) The representative IHC staining of Transforming growth factor (TGFβ1) in HCC tissues; (II) The representative IHC staining of TGFβ1 in adjacent liver tissues; (III) The negative staining of TGFβ1 in HCC tissues; (b) The western immunoblotting results of TGFβ1 in 3 pairs of representative HCC tissues (T) and adjacent liver tissues (N); (c) The IHC scores of TGFβ1 in HCC tissues were significantly higher than one in adjacent liver tissues (p < 0.001); (d) The Spearmen rank test showed that there was positive correlation between TGFβ1 and MRC2 expression in HCC tissues (r = 0.347; p < 0.001).